Osteomyelitis was reported in 12 trials (3, 2, 6, and 1 with canagliflozin, dapagliflozin, ertugliflozin, and ipragliflozin, respectively) for a total of 79 events with SGLT2-is versus 71 events with comparators, thus resulting in a global RRMH of 1.04 [0.76–1.44] (Figure 2). This evidence concerns the gene SLC5A2 and osteomyelitis.